Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma

Key Points

• The aim is to validate the very favorable IMDC risk group in metastatic renal cell carcinoma and assess treatment outcomes.
• Conducted a cohort study
• Compared outcomes of very favorable risk subgroup and favorable risk group
• Analyzed survival rates with different treatment regimens such as VEGF-TT and IO-VE
• Very favorable risk subgroup displayed superior outcomes with VEGF-containing regimens
• IO-IO combination resulted in significantly worse survival
• Suggests that VEGF inhibition is vital for achieving optimal outcomes